Slide 1: Dimerix Investor Call & Presentation (ASX announcement)
Immediate Release DIMERIX INVESTOR CALL & PRESENTATION MELBOURNE, Australia, 1 March 2022: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company invites shareholders to attend its investor webinar held today at For personal use only 11am (AEDT) 1 March 2022. The webinar will cover D
Slide 2: Investor Briefing March 2022
@ Dimerix (ASX:DXB) Investor Briefing 01 March 2022 Authorised for lodgment by the Board of the Company
Slide 3: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 4: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Advancing three ; rs % Phase 3 clinical studies i Wh w Demonstrated
Slide 5: Share price and top shareholders
For personal use only Share price Top shareholders
Slide 6: Development pipeline
Development pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Key milestones . Phase 2a demonstrated encouraging efficacy & safety’; Phase 3 underway (ac) Glomerular Sclerosis CF with regulatory &/or ethics authorisation in multiple countries’, recruitment of 1* patients planned Q1 22,
Slide 7: COVID-19 Respiratory Complications
COVID-19 Respiratory Complications
Slide 8: Potential benefits of DMX-200
Potential benefits of DMX-200 Antiviral medications: Typically effective at preventing damage caused by a virus when administered days of infecti when many are asymptomatic 1. Brown L etal (2021) Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol
Slide 9: Two Phase studies in COVID-19 patients
Two Phase 3 studies in COVID-19 patients ofits. Patients were randomised patients to receive one of: ce NHMR C 41. Angiotensin receptor blocker (ARB) alone Clinical Trials Centre 2. Angiotensin converting enzyme (ACE) inhibitor alone ‘THE UNIVERSITY OF SS 3. ARB simultaneously with DMX-200 SYDNEY RE
Slide 10: Kidney Disease Development Overview
Kidney Disease Development Overview
Slide 11: FSGS phase 3 study design
FSGS phase 3 study design nt ACTIAN3 A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes FSGS CLINICAL STUDY of DMX-200 in patients with primary FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 -1 0 35 104 I il ! 6 oN 2 DMX-200 ® oI 2£f 2 2] = BI 3 a
Slide 12: FSGS phase 3 study locations
FSGS phase 3 study locations Global study with “70 sites in 12 countries: Count Regulatory and/or ethics y approval to proceed ACTIGNS Australia v Argentina v FSGS CLINICAL STUDY Brazil Denmark v France v A randomised, double-blind, multi-centre, placebo- Hong Kong controlled study of renal outcomes
Slide 13: For personal use only
For personal use only
Slide 14: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ❑
Slide 15: Dimerix contact and ESG statement
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Well positioned to deliver against strategic plan Dimerix HQ